Development and evaluation of a prototype of a novel clotting time test to monitor enoxaparin

Pharmaceutical Research

Volumn 29, Issue 1, 2012, Pages 225-235

  Gulati, Abhishek ^a   Faed, James M ^a   Isbister, Geoffrey K ^b,c   Duffull, Stephen B ^a  

^a UNIVERSITY OF OTAGO   (New Zealand)

^b CALVARY MATER NEWCASTLE HOSPITAL   (Australia)

^c UNIVERSITY OF NEWCASTLE   (Australia)

Author keywords

Coagulation network; Enoxaparin; Low molecular weight heparins; Mathematical model; Monitoring

Indexed keywords

ENOXAPARIN; ANTICOAGULANT AGENT; BIOLOGICAL MARKER; BLOOD CLOTTING FACTOR 10A;

ARTICLE; BLOOD CLOTTING TIME; COMPUTER MODEL; CONTROLLED STUDY; DRUG EFFECT; DRUG MONITORING; HEPARINIZATION; IN VITRO STUDY; MATHEMATICAL MODEL; PARTIAL THROMBOPLASTIN TIME; PRIORITY JOURNAL; PROCESS DEVELOPMENT; PROTHROMBIN TIME; SIMULATION; BIOLOGICAL MODEL; BLOOD; BLOOD CLOTTING; BLOOD CLOTTING TEST; DRUG ANTAGONISM; HUMAN; METHODOLOGY; THROMBOSIS;

ANTICOAGULANTS; BIOLOGICAL MARKERS; BLOOD COAGULATION; BLOOD COAGULATION TESTS; DRUG MONITORING; ENOXAPARIN; FACTOR XA; HUMANS; MODELS, BIOLOGICAL; THROMBOSIS;

EID: 84860578340     PISSN: 07248741     EISSN: 1573904X     Source Type: Journal    
DOI: 10.1007/s11095-011-0537-z     Document Type: Article

References (34)

1. Eastham RD, Slade RR. Bleeding, clotting and transfusion. Oxford: Clinical Haematology, Butterworth Heinemann; 1992.
2. Antman EM, McCabe CH, Gurfinkel EP, Turpie AG, Bernink PJ, Salein D, et al. Enoxaparin prevents death and cardiac ischemic events in unstable angina/non-Q-wave myocardial infarction. Results of the thrombolysis in myocardial infarction (TIMI) 11B trial. Circulation. 1999;100:1593-601. (Pubitemid 29477267)
3. Cohen M, Demers C, Gurfinkel EP, Turpie AG, Fromell GJ, Goodman S, et al. A comparison of low-molecular-weight heparin with unfractionated heparin for unstable coronary artery disease. Efficacy and safety of subcutaneous enoxaparin in non-Q-wave coronary events study group. N Engl J Med. 1997;337:447-52. (Pubitemid 27333045)
4. Eriksson BI, Kalebo P, Anthymyr BA, Wadenvik H, Tengborn L, Risberg B. Prevention of deep-vein thrombosis and pulmonary embolism after total hip replacement. Comparison of low-molecular-weight heparin and unfractionated heparin. J Bone Joint Surg Am. 1991;73:484-93.
5. Hirsh J, Warkentin TE, Shaughnessy SG, Anand SS, Halperin JL, Raschke R, et al. Heparin and low-molecular-weight heparin: mechanisms of action, pharmacokinetics, dosing, monitoring, efficacy, and safety. Chest. 2001;119:64S-94S. (Pubitemid 32154195)
6. Hirsh J, Levine MN. Low molecular weight heparin. Blood. 1992;79:1-17.
7. Jorgensen LN, Wille-Jorgensen P, Hauch O. Prophylaxis of postoperative thromboembolism with low molecular weight heparins. Br J Surg. 1993;80:689-704. (Pubitemid 23197710)
8. Leizorovicz A, Haugh MC, Chapuis FR, Samama MM, Boissel JP. Low molecular weight heparin in prevention of perioperative thrombosis. BMJ. 1992;305:913-20.
9. Nurmohamed MT, Rosendaal FR, Buller HR, Dekker E, Hommes DW, Vandenbroucke JP, et al. Low-molecular-weight heparin versus standard heparin in general and orthopaedic surgery: a meta-analysis. Lancet. 1992;340:152-6.
10. Al-Sallami HS, Barras MA, Green B, Duffull SB. Routine plasma anti-Xa monitoring is required for low-molecular-weight heparins. Clin Pharmacokinet. 2010;49:567-71.
11. Hirsh J, Dalen JE, Deykin D, Poller L. Oral anticoagulants. Mechanism of action, clinical effectiveness, and optimal therapeutic range. Chest. 1992;102:312S-26S.
12. Hirsh J, Dalen JE, Deykin D, Poller L. Heparin: mechanism of action, pharmacokinetics, dosing considerations, monitoring, efficacy, and safety. Chest. 1992;102:337S-51S.
13. Hirsh J, Raschke R. Heparin and low-molecular-weight heparin: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest. 2004;126:188S-203S. (Pubitemid 39297954)
14. Boneu B. Low molecular weight heparin therapy: is monitoring needed? Thromb Haemost. 1994;72:330-4. (Pubitemid 24280767)
15. Hirsh J. Heparin. N Engl J Med. 1991;324:1565-74.
16. Dougherty KG, Gaos CM, Bush HS, Leachman DR, Ferguson JJ. Activated clotting times and activated partial thromboplastin times in patients undergoing coronary angioplasty who receive bolus doses of heparin. Cathet Cardiovasc Diagn. 1992;26:260-3.
17. Frank RD, Brandenburg VM, Lanzmich R, Floege J. Factor Xaactivated whole blood clotting time (Xa-ACT) for bedside monitoring of dalteparin anticoagulation during haemodialysis. Nephrol Dial Transplant. 2004;19:1552-8. (Pubitemid 38786750)
18. Lawrence M, Mixon TA, Cross D, Gantt DS, Dehmer GJ. Assessment of anticoagulation using activated clotting times in patients receiving intravenous enoxaparin during percutaneous coronary intervention. Catheter Cardiovasc Interv. 2004;61:52-5. (Pubitemid 38036790)
19. Marmur JD, Anand SX, Bagga RS, Fareed J, Pan CM, Sharma SK, et al. The activated clotting time can be used to monitor the low molecular weight heparin dalteparin after intravenous administration. J Am Coll Cardiol. 2003;41:394-402. (Pubitemid 36164492)
20. Wilson JM, Gilbert J, Harlan M, Bracey A, Allison P, Schooley C, et al. High-dose intravenous dalteparin can be monitored effectively using standard coagulation times. Clin Appl Thromb Hemost. 2005;11:127-38. (Pubitemid 40547996)
21. Greiber S, Weber U, Galle J, Bramer P, Schollmeyer P. Activated clotting time is not a sensitive parameter to monitor anticoagulation with lowmolecular weight heparin in hemodialysis. Nephron. 1997;76:15-9. (Pubitemid 27199033)
22. Henry TD, Satran D, Knox LL, Iacarella CL, Laxson DD, Antman EM. Are activated clotting times helpful in the management of anticoagulation with subcutaneous low-molecular-weight heparin? Am Heart J. 2001;142:590-3. (Pubitemid 32900484)
23. Linkins LA, Julian JA, Rischke J, Hirsh J, Weitz JI. In vitro comparison of the effect of heparin, enoxaparin and fondaparinux on tests of coagulation. Thromb Res. 2002;107:241-4. (Pubitemid 35435383)
24. Rabah MM, Premmereur J, Graham M, Fareed J, Hoppensteadt DA, Grines LL, et al. Usefulness of intravenous enoxaparin for percutaneous coronary intervention in stable angina pectoris. Am J Cardiol. 1999;84:1391-5.
25. Briggs C, Guthrie D, Hyde K, Mackie I, Parker N, Popek M, et al. Guidelines for point-of-care testing: haematology. Br J Haematol. 2008;142:904-15.
26. Perry DJ, Fitzmaurice DA, Kitchen S, Mackie IJ, Mallett S. Point-of-care testing in haemostasis. Br J Haematol. 2010;150:501-14.
27. Samama MM, Martinoli JL, LeFlem L, Guinet C, Plu-Bureau G, Depasse F, et al. Assessment of laboratory assays to measure rivaroxaban-an oral, direct factor Xa inhibitor. Thromb Haemost. 2010;103:815-25.
28. Vukovich T, Proidl S, Teufelsbauer H, Kautzky A, Erlacher L, Luger A, et al. Laboratory monitoring of thromboprophylaxis with low molecular weight and standard heparin. Thromb Res. 1992;66:735-43.
29. Wajima T, Isbister GK, Duffull SB. A comprehensive model for the humoral coagulation network in humans. Clin Pharmacol Ther. 2009;86:290-8.
30. Tanos PP, Isbister GK, Lalloo DG, Kirkpatrick CM, Duffull SB. A model for venom-induced consumptive coagulopathy in snake bite. Toxicon. 2008;52:769-80.
31. Kogan AE, Kardakov DV, Khanin MA. Analysis of the activated partial thromboplastin time test using mathematical modeling. Thromb Res. 2001;101:299-310. (Pubitemid 32206585)
32. O'Leary MA, Isbister GK. A turbidimetric assay for the measurement of clotting times of procoagulant venoms in plasma. J Pharmacol Toxicol Methods. 2010;61:27-31.
33. Conard J, Brosstad F, Lie Larsen M, Samama M, Abildgaard U. Molar antithrombin concentration in normal human plasma. Haemostasis. 1983;13:363-8. (Pubitemid 14152590)
34. Lindhoff-Last E, Samama MM, Ortel TL, Weitz JI, Spiro TE. Assays for measuring rivaroxaban: their suitability and limitations. Ther Drug Monit. 2010;32:673-9.